MyFinsight
Home
Blog
About
Contact
Download
Download image
Short-term investments
(amortized cost of 307,394)
$307,610K
Cash and cash
equivalents
$207,820K
Prepaid expenses and
other current assets
$11,015K
Refundable income taxes
$1,793K
Grants receivable
$475K
Research and development
tax credits...
$280K
Total current assets
$528,993K
Long-term investments
(amortized cost of 74,475)
$74,614K
Research and development
tax credits...
$7,955K
Property and equipment,
net
$5,175K
Right of use assets
$5,129K
Other assets
$898K
Restricted cash
$319K
Total assets
$623,083K
Total liabilities and
stockholders equity
$623,083K
Total stockholders
equity
$493,801K
Total liabilities
$129,282K
Accumulated deficit
-$123,123K
Accumulated other
comprehensive loss
-$16,190K
Additional paid-in capital
$633,070K
Total current
liabilities
$70,274K
Unrecognized tax benefits
$48,790K
Grants repayable, net
of current portion
$6,606K
Lease liabilities,
net of current...
$3,612K
Common stock, 0.001 par
value 150,000,000...
$44K
Accrued clinical trial
costs
$36,462K
Accrued personnel
expenses
$23,774K
Accounts payable
$6,249K
Lease liabilities
$1,516K
Deferred income
$1,477K
Other accrued
expenses
$796K
Back
Back
Balance Sheet
source: myfinsight.com
iTeos Therapeutics, Inc. (ITOS)
iTeos Therapeutics, Inc. (ITOS)